USCAREPHARM’s MA Division participated in IMCAS Americas 2026, held in São Paulo, Brazil from March 13 to 15, 2026, where it introduced its global medical aesthetics brand ERBELLA. Through its participation, the company established strategic partnerships with local medical professionals and distributors, officially launching its efforts to enter the South American aesthetics market with Brazil as its regional hub.

By taking part in IMCAS Americas 2026, one of the largest aesthetic medicine congresses in Latin America, USCAREPHARM’s MA Division took its first step toward expanding into the South American aesthetics market. IMCAS Americas is a prestigious conference attended by dermatologists, plastic surgeons, and aesthetic treatment professionals from across Latin America, serving as a key platform for identifying the latest technological trends and market developments. Through this event, USCAREPHARM directly introduced the strengths of the ERBELLA brand to local medical professionals and confirmed the strong interest in K-beauty medical aesthetic solutions.

During the event, USCAREPHARM’s MA Division held intensive business meetings with major medical professionals and distribution companies from Brazil and other South American countries. Detailed discussions covered product supply systems, distribution channel development, and potential areas of collaboration. The company also explored ways to provide tailored solutions that reflect local skin characteristics and aesthetic needs. In particular, ERBELLA’s technology received strong recognition for its ability to align with local treatment trends that favor natural and gradual improvements.

USCAREPHARM also used its participation in IMCAS Americas not simply as a product promotion opportunity, but as a comprehensive market research initiative for the South American aesthetics sector. The company closely analyzed skin characteristics, preferred treatment trends, medical environments, and regulatory systems in Brazil and across South America. Based on these on-site insights, it plans to develop a localized product portfolio and medical education programs for ERBELLA’s future launch in the South American market.

USCAREPHARM’s MA Division plans to position Brazil as a key strategic base for its South American aesthetics business and pursue a phased market expansion strategy. While proceeding step by step with local regulatory and licensing procedures, the company also aims to strengthen professional training for medical practitioners through academic seminars and hands-on workshops in major cities. By continuing to participate in major global congresses and industry exhibitions, USCAREPHARM intends to further enhance brand awareness and establish itself as a total aesthetics solution partner offering not only products, but also treatment know-how and education.

A representative from USCAREPHARM’s MA Division stated, “Brazil is the largest aesthetics market in South America and a key region leading global medical beauty trends. Through our participation in IMCAS Americas, we confirmed the positive response to ERBELLA products from local medical professionals and partners.” The representative added, “With a product portfolio and education programs optimized for the characteristics of the local market, we aim to grow ERBELLA into a leading aesthetics brand in South America and further elevate the global status of K-beauty aesthetics.”